Ginsenoside Rk3 Inhibits the Extramedullary Infiltration of Acute Monocytic Leukemia Cell via miR-3677-5p/CXCL12 Axis

Table 1

The patients’ clinical manifestation and general data.

Family name	Group case no.	FAB classification	BM blast cells (%)	Extramedullar infiltrating organ	Chemotherapy regimens	Chemotherapy response	miR-3677-5p expression	CXCL12 expression	CXCR4 expression
Chen	EMI-1	M5a	49	Lung	DAV	NR	0.4	2.4	3.9
Tao	EMI-2	M5a	68	Pancrea, spleen, and neck lymph gland	DAV	NR	0.5	2.9	3.1
Chen	EMI-3	M5b	60	Lymph gland of whole body	DA	CR	0.2	2.8	2.2
Ping	EMI-4	M5b	80	Spleen and neck lymph gland	DA	NR	0.3	3.8	2.1
Sun	EMI-5	M5a	87	Spleen and groin lymph gland	DA	NR	0.4	2.9	2.5
Guo	EMI-6	M5a	86	Neck lymph gland	DA	CR	0.4	3.1	2.1
Du	EMI-7	M5b	73	Lung	DAV	NR	0.4	2.8	3.2
Gong	EMI-8	M5b	53	Neck lymph gland	DA	PR	0.3	3.1	3.1
Qi	EMI-9	M5a	67	Groin lymph gland	DAV	NR	0.5	3.0	1.6
Lou	EMI-10	M5a	61	Spleen and neck lymph gland	DAV	CR	0.4	2.4	2.5
Mao	N-EMI-1	M5b	26	—	DA	CR	0.8	1.7	1.5
Yuan	N-EMI-2	M5a	37	—	VA	NR	0.6	1.5	2.0
Rao	N-EMI-3	M5b	53	—	VA	PR	0.8	1.6	1.6
Zhou	N-EMI-4	M5a	75	—	VA	PR	0.6	2.2	1.6
Wang	N-EMI-5	M5a	36	—	DA	PR	0.9	2.0	1.3
Cheng	N-EMI-6	M5b	75	—	DAV	PR	0.8	2.0	1.7
Wang	N-EMI-7	M5b	42	—	DAV	PR	0.8	1.9	1.8
Zhang	N-EMI-8	M5a	34	—	DAV	CR	0.8	1.4	1.8
Cheng	N-EMI-9	M5b	31	—	VA	CR	0.7	1.7	1.7
Wang	N-EMI-10	M5a	56	—	DAV	CR	0.5	2.0	1.2

Chemotherapy: (1) DAV. DNR + Ara-C + venetoclax; (2) DA. DNR + Ara-C; (3) VA. venetoclax + Ara-C.